公开(公告)号：US20180353553A1

公开(公告)日：2018-12-13

申请号：US15901962

申请日：2018-02-22

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali ,  Shaheen Majeed

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali ,  Shaheen Majeed

IPC: A61K35/742 ,  A61P1/14 ,  A61K9/00 ,  A61K9/48 ,  A61K9/20 ,  A23L33/135

CPC classification number: A61K35/742 ,  A23L33/135 ,  A23V2002/00 ,  A61K9/0053 ,  A61K9/0056 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2054 ,  A61K9/4866 ,  A61K2035/115 ,  A61P1/14

Abstract: Disclosed is the hypolipidemic potential of Bacillus coagulans. More specifically the invention discloses the cholesterol lowering potential of Bacillus coagulans MTCC 5856 and therapeutic/biological indications thereof.

公开(公告)号：US20180344781A1

公开(公告)日：2018-12-06

申请号：US15995454

申请日：2018-06-01

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali ,  Shaheen Majeed ,  Lakshmi Mundkur

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali ,  Shaheen Majeed ,  Lakshmi Mundkur

IPC: A61K35/742 ,  A61K9/00 ,  A61P17/14 ,  A61P17/08 ,  A61K8/99 ,  A61Q7/00

Abstract: Disclosed are hair care compositions containing partially purified extracellular metabolite preparation from strains of Bacillus coagulans. Specifically, the uses of compositions containing extracellular metabolite preparation from a strain of Bacillus coagulans for increasing hair growth, inhibition of 5α-reductase and proliferation of follicle dermal papilla cells and in the management of androgenic alopecia, are disclosed.

公开(公告)号：US20180000873A1

公开(公告)日：2018-01-04

申请号：US15198158

申请日：2016-06-30

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

IPC: A61K35/742 ,  A61K35/00

CPC classification number: A61K35/742 ,  A61K2035/11

Abstract: The present invention discloses the use of probiotics for therapeutic management of major depressive disorder (MDD). Specifically, the invention discloses the method of therapeutically managing MDD in mammals with Irritable bowel syndrome using probiotic strain Bacillus coagulans MTCC 5856.

公开(公告)号：US09681666B2

公开(公告)日：2017-06-20

申请号：US15214685

申请日：2016-07-20

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

IPC: A61K35/00 ,  A01N63/02 ,  C12N1/20 ,  C12R1/07 ,  A01N31/08 ,  A01N37/12 ,  C12R1/085 ,  C12R1/19 ,  C12R1/385 ,  C12R1/42 ,  C12R1/445 ,  C12R1/45 ,  C12R1/46

CPC classification number: A01N63/02 ,  A01N31/08 ,  A01N37/12 ,  C12N1/20 ,  C12R1/07 ,  C12R1/085 ,  C12R1/19 ,  C12R1/385 ,  C12R1/42 ,  C12R1/445 ,  C12R1/45 ,  C12R1/46 ,  A01N65/08

Abstract: The antimicrobial effect of extracellular metabolite composition from Bacillus coagulans MTCC 5856 and composition comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis is described.

公开(公告)号：US20170096700A1

公开(公告)日：2017-04-06

申请号：US15276912

申请日：2016-09-27

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

IPC: C12Q1/68

CPC classification number: C12Q1/689 ,  C12Q2600/156 ,  C12Q2600/158

Abstract: The present invention discloses novel oligonucleotide primer sequences BC1, BC2 and BC3 for the identification of Bacillus coagulans. The invention also discloses a PCR based method for the identification of Bacillus coagulants using the aforesaid primers, wherein positive amplification with primer sets BC1, BC2 and negative amplification with primer set BC3 confirms the presence of Bacillus coagulans.

公开(公告)号：US09579352B2

公开(公告)日：2017-02-28

申请号：US14536701

申请日：2014-11-10

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Natarajan Sankaran ,  Priti Vaidyanathan ,  Sivakumar Arumugam ,  Suresh Kumar Karri

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Natarajan Sankaran ,  Priti Vaidyanathan ,  Sivakumar Arumugam ,  Suresh Kumar Karri

IPC: A01N63/00 ,  A61K35/742 ,  A61K35/00

CPC classification number: A61K35/742 ,  A61K2035/115

Abstract: The present invention discloses a process for the therapeutic management of diarrhea predominant irritable bowel syndrome in humans comprising the oral administration of Bacillus coagulans SBC37-01, MTCC 5856 (containing not less than 2 billion spores) along with standard treatment of care in a specific manner.

Abstract translation: 本发明公开了一种用于治疗人体腹泻主要肠易激综合征的治疗方法，其包括口服施用凝结芽孢杆菌SBC37-01，MTCC5856（含有不少于20亿个孢子）以及以特定方式进行护理的标准治疗 。

公开(公告)号：US20160324161A1

公开(公告)日：2016-11-10

申请号：US15214669

申请日：2016-07-20

Applicant: Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

Inventor： Muhammed Majeed ,  Kalyanam Nagabhushanam ,  Sivakumar Arumugam ,  Furqan Ali

IPC: A01N63/02 ,  C12R1/07

CPC classification number: A01N63/02 ,  A01N31/08 ,  A01N37/12 ,  C12N1/20 ,  C12R1/07 ,  C12R1/085 ,  C12R1/19 ,  C12R1/385 ,  C12R1/42 ,  C12R1/445 ,  C12R1/45 ,  C12R1/46 ,  A01N65/08

Abstract: Disclosed is a method for producing partially purified extracellular metabolite preparation from the probiotic bacterial strain Bacillus coagulans SBC-37 (Deposited in the Microbial Type Culture Collection and Gene Bank as strain number MTCC 5856) exhibiting 99% genetic homology with the known bacterial strains Bacillus coagulans ATCC 31284, Bacillus coagulans NBRC 3887 and Bacillus coagulans ATCC 7050. Also disclosed is the anti-microbial profile of said extracellular metabolite preparation against a panel of microbial pathogens, including synergistic anti-microbial effects of preparation when combined with a synergistic preservative blend comprising from about 61% w/w of thymol, about 38% of monolaurin and about 1% w/w of magnolol obtained from supercritical fluid extracts of Magnolia officinalis. The extracellular metabolite preparation alone or the combination of said extracellular metabolite preparation and preservative blend also inhibits microbial biofilm formation in a synergistic manner.